Obesity drug shows promise in miceToronto SunCHICAGO - A compound similar to Sanofi-Aventis' once-promising weight loss drug Acomplia helped obese mice lose weight and .
Vivus's Obesity Drug Raises Familiar Questions - Seeking Alpha (blog)
Vivus's Obesity Drug Raises Familiar QuestionsSeeking Alpha (blog)That's what took the Fen-Phen combination off the market, and what torpedoed Acomplia (rimonabant) and the other CB-1 compounds before they'd even been .
Jefferies Concern About Neuropsychiatric Profile Of Qnexa: VVUS - Benzinga
Jefferies Concern About Neuropsychiatric Profile Of Qnexa: VVUSBenzingaJefferies adds, “The most recently reviewed obesity drug was Acomplia (rimonabant), which was denied approval due to neuropsychiatric concerns.
Qnexa: Miracle diet drug? - Helium
Qnexa: Miracle diet drug?HeliumTwo years ago studies were discontinued for Acomplia, due to psychiatric side effects.
Investors All Worried About Qnexa FDA Panel Review This Week (ARNA, OREX, VVUS) - TapeBeat
Investors All Worried About Qnexa FDA Panel Review This Week (ARNA, OREX, VVUS)TapeBeatIn June 2007, the FDA rejected Sanofi-Aventis' Acomplia saying that the drug's benefits did not outweigh its risks.